Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：27
作者：
Diedhiou, Demba [1 ,2 ]
Cuny, Thomas [1 ]
Sarr, Anna [2 ]
Diop, Said Norou [2 ]
Klein, Marc [1 ]
Weryha, Georges [1 ]
机构：
[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France
[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal
来源：
ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期
关键词：
Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;
D O I：
10.1016/j.ando.2015.10.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：650 / 657
页数：8
相关论文
共 50 条
[41]   Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review [J].
Kendler, David L. ;
Cosman, Felicia ;
Stad, Robert Kees ;
Ferrari, Serge .
ADVANCES IN THERAPY, 2022, 39 (01) :58-74
[42]   Clinical use of denosumab for the treatment for postmenopausal osteoporosis [J].
Lewiecki, E. Michael .
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (12) :2807-2812
[43]   Denosumab for treatment of postmenopausal osteoporosis [J].
Chitre, Mona ;
Shechter, David ;
Grauer, Andreas .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (15) :1409-1418
[44]   Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials [J].
Kobayashi, Takaomi ;
Morimoto, Tadatsugu ;
Ito, Koji ;
Mawatari, Masaaki ;
Shimazaki, Takafumi .
OSTEOPOROSIS INTERNATIONAL, 2024, 35 (08) :1377-1393
[45]   Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis [J].
Julissa Serrano, Ana ;
Begona, Leire ;
Anitua, Eduardo ;
Cobos, Raquel ;
Orive, Gorka .
GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (12) :1005-1014
[46]   Denosumab in osteoporosis [J].
Diab, Dima L. ;
Watts, Nelson B. .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (02) :247-253
[47]   Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study [J].
Kobayakawa, Tomonori ;
Kanayama, Yasuhide ;
Hirano, Yuji ;
Nakamura, Yukio .
SCIENTIFIC REPORTS, 2024, 14 (01)
[48]   Efficacy of statins for osteoporosis: a systematic review and meta-analysis [J].
An, T. ;
Hao, J. ;
Sun, S. ;
Li, R. ;
Yang, M. ;
Cheng, G. ;
Zou, M. .
OSTEOPOROSIS INTERNATIONAL, 2017, 28 (01) :47-57
[49]   Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study [J].
Kobayakawa, Tomonori ;
Miyazaki, Akiko ;
Takahashi, Jun ;
Nakamura, Yukio .
BONE, 2022, 162
[50]   Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis A systematic review and meta-analysis [J].
Peng, Lihua ;
Luo, Qian ;
Lu, Hui .
MEDICINE, 2017, 96 (49)
12345